The story has been revised to reflect changes made by Life Technologies to its third-quarter revenue and EPS figures as a result of a $48.6 million verdict against the company.

NEW YORK (GenomeWeb News) – Life Technologies reported after the close of the market on Thursday that its third-quarter revenues slid 2 percent year over year, though it beat consensus Wall Street estimates on the top and bottom line.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.